Equities

Theratechnologies Inc

Theratechnologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)1.78
  • Today's Change-0.04 / -2.20%
  • Shares traded32.94k
  • 1 Year change+4.71%
  • Beta1.7874
Data delayed at least 15 minutes, as of Nov 08 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Theratechnologies Inc has grown net income from a loss of -47.24m to a smaller loss of -23.96m despite relatively flat revenues.
Gross margin76.97%
Net profit margin-3.75%
Operating margin10.72%
Return on assets-5.00%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, Theratechnologies Inc increased its cash reserves by 42.93%, or 10.24m. Cash Flow from Financing totalled 14.78m or 18.07% of revenues. In addition the company used 5.68m for operations while cash from investing totalled 1.11m.
Cash flow per share-0.0097
Price/Cash flow per share--
Book value per share-0.5952
Tangible book value per share-0.9405
More ▼

Balance sheet in USDView more

Theratechnologies Inc has a Debt to Total Capital ratio of 151.57%.
Current ratio1.08
Quick ratio0.9691
Total debt/total equity--
Total debt/total capital1.52
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.